

# CITATION REPORT

List of articles citing

## Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within Vigibase

DOI: 10.1007/s40264-015-0337-1  
Drug Safety, 2015, 38, 1179-86.

**Source:** <https://exaly.com/paper-pdf/62476833/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , <b>2016</b> , 128, 1625-30	2.2	50
23	Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlook. <i>Seminars in Hematology</i> , <b>2016</b> , 53 Suppl 1, S39-42	4	1
22	Lusutrombopag: First Global Approval. <i>Drugs</i> , <b>2016</b> , 76, 155-8	12.1	55
21	[Epidemiology and pharmacoepidemiology of immune thrombocytopenia]. <i>Revue De Medecine Interne</i> , <b>2017</b> , 38, 444-449	0.1	7
20	Emerging drugs for immune thrombocytopenia (ITP). <i>Expert Opinion on Emerging Drugs</i> , <b>2017</b> , 22, 27-38	3.7	10
19	A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia. <i>Pediatric Hematology and Oncology</i> , <b>2017</b> , 34, 73-89	1.7	9
18	[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study]. <i>Revue De Medecine Interne</i> , <b>2017</b> , 38, 167-175	0.1	10
17	Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 928-937	3.3	28
16	Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. <i>Scientific Reports</i> , <b>2018</b> , 8, 576	4.9	8
15	A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 192-195	5.1	2
14	Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198504	3.7	20
13	Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 829	5.6	5
12	Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , <b>2019</b> , 10, 2040620719841735	5.7	36
11	Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis. <i>Platelets</i> , <b>2019</b> , 30, 828-835	3.6	12
10	Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag. <i>Platelets</i> , <b>2020</b> , 31, 993-1000	3.6	6
9	Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 597-600	5.1	1
8	Eltrombopag-Associated Cerebral Venous Thrombosis. <i>American Journal of Therapeutics</i> , <b>2021</b> , 28, e167-e169	0	0

7	Eltrombopag-related renal vein thromboembolism in a patient with immune thrombocytopenia: A case report. <i>World Journal of Clinical Cases</i> , <b>2021</b> , 9, 2611-2618	1.6	1
6	Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 456-465	4.5	2
5	Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. <i>Medical Journal of Australia</i> , <b>2021</b> , 216, 43	4	0
4	The challenges of pharmacoepidemiology of orphan drugs in rare diseases. <i>Therapie</i> , <b>2020</b> , 75, 215-220	3.8	1
3	Refractory Coronary Stent Thrombosis in a Patient with Chronic Immune Thrombocytopenia on Eltrombopag. <i>Acta Cardiologica Sinica</i> , <b>2021</b> , 37, 542-545	1.1	
2	Immune Thrombocytopenic Purpura and Paradoxical Thrombosis: A Systematic Review of Case Reports. <b>2022</b> ,		0
1	Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism. <b>2023</b> ,		0